T1	Participants 51 78	in metastatic breast cancer
T2	Participants 242 332	in patients with metastatic breast cancer (MBC) who had previously received anthracyclines
T3	Participants 366 378	210 patients
T4	Participants 793 809	the 204 patients
T5	Participants 1104 1120	the 208 patients
T6	Participants 1541 1544	MBC
